Par launches generic AndroGel

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical on Wednesday announced that it has begun shipping its generic version of AbbVie’s AnroGel (testosterone gel 1%) in 2.5-g and 5-g foil packets, which contain 25- and 50-mg of testosterone, respectively. Par recently received approval from the Food and Drug Administration for the generic, five years ahead of the expiration of the relevant patent, Par said

The drug is used for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, the company said. Annual U.S. sales of testosterone gel 1% packets are approximately $206 million, according to the company.